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Abstract ADHDaffectsover5%ofchildrenworldwide.It
is typically treated with stimulant medications, and meth-
ylphenidate (MPH) is the most commonly prescribed. This
study investigated the effectiveness, on symptoms and
impairment, and safety of Equasym XL
, a combination of
30% immediate-release and 70% modiﬁed-release MPH, in
the treatment of ADHD in daily clinical practice. This open-
label, observational, post-marketing surveillance study was
conductedin169centresinGermany.Eligiblepatients,aged
6–17 years, were diagnosed with ADHD and about to begin
treatment with Equasym XL
. Effectiveness was assessed
by physicians using the clinical global impression (CGI)
severity and improvement scales; teachers and parents
completed questionnaires evaluating ADHD symptoms and
behavioural problems (DAYAS, FBB-ADHD and SDQ-P).
Assessments were carried out at baseline, after 1–3 and
6–12 weeksoftreatment.Of852enrolledpatients,822were
evaluable; 25.30% were treatment naı ¨ve, 69.84% had pre-
viously received different MPH formulations, and 4.87%
hadreceivedothermedications.ADHDsymptomsimproved
from baseline to last visit for the majority of patients for all
outcome measures. According to physician ratings of core
ADHD symptoms, 75.73% of patients showed improve-
ments on the CGI-Improvement scale, 17.77% had no
change, and 6.50% worsened. In teacher and parent ratings,
theeffectivenessofEquasymXL
wasratedbetterthanprior
therapy at all measured time points across the day, particu-
larly late morning (teachers) and early afternoon (parents).
Equasym XL
 was generally well tolerated; only 3.16% of
patients permanently discontinued treatment due to adverse
events. EquasymXL
iseffectiveandwelltoleratedindaily
clinical practice.
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Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is the most
commonly diagnosed neurobehavioural disorder in child-
hood, affecting over 5% of children worldwide [33].
Although there are differences between United States and
European diagnostic criteria [6], according to both the
Diagnostic and Statistical Manual of the American Psychi-
atric Association (DSM-IV-TR) and the International Clas-
siﬁcation of Diseases (tenth edition, ICD-10), ADHD (or
hyperkinetic disorder [HKD] according to ICD-10) is char-
acterised by inappropriate levels of inattention, hyperactiv-
ity and impulsivity, which constitute the so-called ADHD
core symptoms. These are often accompanied by comorbid
symptoms, such as aggressive behaviour, depressive mood,
anxiety and tics, by learning difﬁculties [11], and by
impairmentofsocialfunctioning[15,29].ADHDsymptoms
are known to decline with age, and approximately half of
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diagnostic criteria for the disorder when they reach adult-
hood; however, up to 50% of childhood ADHD cases show
continued clinically signiﬁcant symptoms during adoles-
cence and adult life, which can cause serious impairments in
everyday life and increase the risk for drug dependence,
depression and anxiety disorder [1, 17].
For decades, ADHD has been treated with stimulant
medications, which in most cases produce a rapid and
dramatic improvement in ADHD symptoms and in the
behaviour of affected children [6]. The use of stimulants
for the management of ADHD has caused increasing public
concern that it might predispose children to substance
abuse as adolescents or adults. However, several studies
have been conducted to address this issue, and there is no
consistent evidence that stimulant treatment in childhood
or during high school leads to a higher risk of drug use and
addiction [5]. Methylphenidate (MPH) is the most com-
monly prescribed stimulant for children with ADHD. It is
believed to inhibit the reuptake of dopamine and nor-
adrenaline into the presynaptic neuron, increasing their
concentration in the extra-neuronal space and therefore
enhancing neurotransmission [3]. MPH is mainly metabo-
lised by de-esteriﬁcation into ritalinic acid, which is
pharmacologically inactive; this results in a short half-life
of 2.0–3.0 h and a short duration of action. The maximum
plasma concentration (Cmax) of MPH, and consequently its
maximum effect, is reached 1.5–2.0 h after dosing [31].
Conventional, immediate-release (IR) MPH formulations
have been used since the 1960s for the treatment of ADHD.
Due to the short duration of action, MPH-IR needs to be
administered repeatedly during the day to maintain effec-
tiveness, 2–3 daily doses being required for most children
[29]. Multiple dosing can be problematic, as it can cause
adherence issues and complications related to privacy, stig-
matisation by classmates, potential abuse and accountability
of the school administration [25]. To overcome these prob-
lems, new long-acting formulations of MPH have been
developed recently that combine IR and modiﬁed-release
(MR) components [20, 32]. These MPH-MR formulations
provide a rapid onset of therapeutic effect, while having a
sufﬁcient duration to eliminate the need for additional doses;
furthermore, they have a biphasic plasma concentration pro-
ﬁle that avoids acute tolerance.
Equasym XL
1 (Shire Pharmaceuticals Ireland Limited,
Ireland) is a combination of MPH-IR and MR that uses a
multi-particulate bead delivery system (Diffucaps
 tech-
nology, Eurand Pharmaceuticals, USA); each Equasym
XL
 capsule contains 30% MPH-IR-coated beads and 70%
MPH-MR-coated beads. Equasym XL
 produces an initial
fast increase in MPH plasma concentration followed by a
second increase after approximately 3 h, and therapeutic
plasma concentration is maintained for about 8 h [40, 44].
Equasym XL
 has a good safety proﬁle and is effective in
controlling ADHD symptoms in children aged 6 years and
older throughout a period consistent with the school day
and homework time, depending on the length of the school
day [23]; it has been proven as effective as MPH-IR given
twice daily [19].
Open-label studies can provide valuable data on thera-
peutic effects by reﬂecting the real-life setting better than
controlled clinical trials [39]. Although clinical effective-
ness of Equasym XL
 has also been shown in an open-label
study [12], no observational study has yet investigated the
effectiveness of this MPH formulation using a structured
combination of physician, teacher and parent ratings, as has
been done for another MPH-MR formulation, Concerta

(Janssen-Cilag,HighWycombe,UK),inbothEuropean[24,
35] and Korean [26] populations. The OBSEER (OBserva-
tionofSafetyandEffectivenessofEquasymXL
inRoutine
care) study was a non-controlled, non-interventional, post-
marketing surveillance study conducted in Germany,
designed to gain new insights into the effectiveness and
safety of treatment with Equasym XL
 under routine care
conditions. The study included children diagnosed with
ADHDorHKD—eitherpreviouslyuntreatedortreatedwith
different MPH formulations, other drugs or non-pharma-
ceutical therapies—for whom therapy with Equasym XL

was already planned by the attending physician. The obser-
vation period for each patient was 6–12 weeks after the ﬁrst
use of Equasym XL
, and effectiveness and safety were
assessed by physicians, parents and teachers.
Methods
Participants
The study included male and female patients aged
6–17 years with a conﬁrmed diagnosis of ADHD according
to DSM-IV-TR (diagnostic codes 314.00 or 314.01) [2]o r
HKD according to ICD-10 (diagnostic codes F90.0, F90.1
or F90.8) [46], for whom therapy with Equasym XL
 (10/
20/30 mg once daily) was already intended by the attend-
ing physician. Medication with long-acting MPH had to be
indicated, and patients had to be attending school. Exclu-
sion criteria included contraindications according to the
summary of product characteristics and the presence of a
mental handicap.
1 Equasym XL is the UK trade name, and is registered and marketed
by Shire in the following countries under the following trademarks:
Denmark, Equasym Depot; Finland, Equasym Retard; France,
Quasym LP; Germany, Equasym Retard; Ireland, Equasym XL;
Netherlands, Equasym XL; Norway, Equasym Depot; Sweden,
Equasym Depot; South Korea, Metadate CD; Mexico, Metadate
CD. Information correct at August 2011.
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This was a non-interventional, non-controlled, multicentre,
prospective, observational, post-marketing surveillance
study conducted in 169 centres in Germany in accordance
with local regulations and under the therapeutic responsi-
bility of the attending physicians; ethics or institutional
review board approval was not required for this study.
Written informed consent was obtained from parents.
Physicians (specialists in paediatrics and/or child and
adolescent psychiatry) were asked to select appropriate
patients for whom therapy with Equasym XL
 was indi-
cated. The required examinations were recorded at baseline
(Visit 1), at a follow-up visit 1–3 weeks after the ﬁrst use
of Equasym XL
 (Visit 2) and at a ﬁnal visit 6–12 weeks
after the ﬁrst use of Equasym XL
 (Visit 3). The infor-
mation collected at Visit 1 included general data for the
patient (sex, age, height, body weight, type of school and
class), oral history of ADHD (duration, diagnosis in ther-
apy-naı ¨ve patients according to the diagnostic checklist for
HKD [DCL-ADHD] [14], timing of severe ADHD symp-
toms, current ADHD treatment including dose and
administration mode), previous pharmaceutical and non-
pharmaceutical treatment of ADHD, concomitant diseases
and medications, rationale for Equasym XL
 treatment in
therapy-naı ¨ve patients and for switching therapy in previ-
ously treated patients, and details of the planned treatment
with Equasym XL
. The study started on 2 November
2006; inclusion of patients concluded on 28 February 2007,
and observation was completed on 27 December 2007.
Outcome measures
Effectiveness was assessed by physicians using the clinical
global impression severity (CGI-S) and Improvement
(CGI-I) scales to rate ADHD core symptoms (inattention,
hyperactivity and impulsivity) and disease-associated
problems (aggressive behaviour, depressive mood, anxiety,
tics and learning difﬁculties). CGI-S and CGI-I scores were
recorded at each study visit. Categories for evaluation of
CGI-S were as follows: 0 = normal; 1 = mild; 2 = mod-
erate; 3 = severe. Categories for CGI-I during treatment,
compared with the conditions before treatment with Equ-
asym XL
, were as follows: -3 = very strongly wors-
ened; -2 = strongly worsened; -1 = slightly worsened;
0 = unchanged, ?1 = slightly improved; ?2 = strongly
improved; ?3 = very strongly improved.
Teachers and parents completed the German ADHD
Symptom Checklist (Fremdbeurteilungsbogen fu ¨r Auf-
merksamkeitsdeﬁzit-Hyperaktivita ¨tssto ¨rung, FBB-ADHD)
[9, 16] for each visit. FBB-ADHD is part of the German
Diagnostic System for Mental Disorders in Children and
Adolescents (DISYPS-II) [13] and assesses the diagnostic
criteria for ADHD according to DSM-IV-TR and for HKD
according to ICD-10. The presence of 20 symptom items is
rated on a scale ranging from 0 = not at all to 3 = very
much, with higher scores indicating more severe symp-
toms. Nine symptom items are combined into a subscale
assessing inattention, and 11 items are combined to assess
hyperactivity and impulsivity; the total symptom score
(ADHD total) covers all 20 symptom items. In addition,
four items evaluate functional impairment with respect to
school performance, relationship towards adults and chil-
dren, and the subjective level of suffering (functional
impairment subscale), and six items assess competences
regarding attentive, reﬂexive and enduring behaviour
(attention-reﬂexivity subscale). Scale scores represent the
sum of the individual item scores divided by the number of
items in each respective scale. The reliability and validity
of the scale scores in parent and teacher ratings have been
established in several studies [8, 13, 16].
Teachers and parents also assessed ADHD symptoms
and other externalising problems for each visit using the
Day Proﬁle of ADHD Symptoms (DAYAS) [7]. The day
proﬁle of ADHD assessment is a new rating scale that
assesses the daily proﬁle of ADHD externalising symptoms
from early morning until bedtime. The rating scale evalu-
ates six items: (1) hyperactivity, (2) inattention, (3)
impulsivity, (4) oppositional behaviour, (5) aggressive
behaviour and temper tantrums and (6) a global rating of
problem behaviour. The teacher version of the question-
naire (DAYAS-T) considers the ﬁrst and second part of the
morning at school (in Germany, children usually visit
school only in the morning), while the parent version
(DAYAS-P) considers four daily periods: early morning
(before school), early afternoon until 4.00 pm, late after-
noon until 7.00 pm and evening. Parents and teachers rate
the items in each period on a four-point scale using the
following values: 0 = not at all; 1 = just a little;
2 = pretty much; 3 = very much. The total score (‘overall
assessment’) is the sum of the six item scores per time
period divided by the number of items; in addition, the ﬁrst
three items are combined into the subscale ‘ADHD symp-
toms’, and items 4 and 5 are combined into the subscale
‘oppositional deﬁant disorder symptoms (ODD)’. Ratings
were conducted during the week preceding each assess-
ment point (Visit 1, Visit 2 and Visit 3) and cover the
typical behaviour of the child at different times of the day
during that week. The reliability and validity of both the
parent and the teacher versions of DAYAS have been
established in several studies [7].
Parents were also asked to complete the Strengths and
Difﬁculties Questionnaire (SDQ-P) at baseline. SDQ is a
brief behavioural screening questionnaire [21], covering
ﬁve scales: emotional symptoms, hyperactivity, conduct
problems, peer relationship problems and pro-social
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were combined into an overall difﬁculties score as the sum
of the four problem scales (i.e. excluding pro-social
behaviour). Each scale was classiﬁed as normal, borderline
or abnormal according to the thresholds established by
Woerner et al. [45] and Rothenberger et al. [38] based on
German population norms.
Adverse events
Adverse events (AEs) were evaluated by the treating
physician at each study visit, coded according to the
Medical Dictionary for Regulatory Activities (MedDRA)
version 11.1 and classiﬁed into AEs and serious AEs.
Physicians were also asked to record whether the AE
occurred during previous treatment or while receiving
Equasym XL
. Criteria of seriousness included occur-
rences leading to death, life-threatening conditions, hospi-
talisation or prolongation of hospitalisation, persistent
injury/disability, incapacity for work, medically signiﬁcant
conditions and congenital abnormalities/birth defects.
Statistical analysis
The study planned to recruit a representative sample of
1,000 patients from 200 physicians, aiming for ﬁve patients
per participating physician. This sample size was calcu-
lated to allow detection of any rare adverse drug reactions,
with a power of 86% for an event with a probability of 0.2,
and 63% for an event with a probability of 0.1%.
Absolute, relative and adjusted relative frequencies (i.e.
omitting patients with missing data) were calculated.
Multiple entries were possible for some items and were
counted; therefore, the sum of relative frequencies could
exceed 100%. The number of patients giving multiple
replies was recorded in each case. To assess the effects
over time on the outcome variables, repeated measures
analyses of variance were conducted post hoc using mul-
tivariate analysis of variance (MANOVA), and effect sizes
[28, 37] were calculated using Cohen’s d [10] for depen-
dent samples, by dividing the difference between the means
of Visit 1 and Visit 3 with a variable including the pooled
standard deviations (SD) for Visits 1 and 3, and the
bivariate correlation (r) between the two visits, as follows:
d ¼
Meanvisit1   Meanvisit3 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðSDvisit1Þ
2 þð SDvisit3Þ
2   2   rvisit1;visit3   SDvisit1   SDvisit3
q
In order to calculate (post hoc) the normalisation rates
for ADHD symptoms and functional impairment, a cut-off
of 1 was deﬁned on the ADHD total score and the
functional impairment score obtained at Visit 3 on the
FBB-ADHD scale (both parent- and teacher-rated). The
same cut-off was used in the Multimodal Treatment study
of ADHD (MTA) study on similar rating scales assessing
ADHD symptoms as deﬁned by DSM-IV [41]; this cut-off
was based on the ICD-10/DSM-IV criteria, which state that
low severity of the speciﬁed behaviours (i.e. in the range
from 0 = not at all to 1 = just a little on the FBB-ADHD
scale) would not be sufﬁcient to qualify them as symptoms
of ADHD or ODD. In addition, norms for the FBB-ADHD
parent-rated scores show that approximately 75–80% of
school-age children manifest a total score of 1 or lower
[13].
Results
In total, 852 patients were recruited to the study, of whom
822 were considered evaluable; 30 patients were excluded
from the analysis because of invalid data. Of the 822
evaluable patients, 777 completed all three planned visits.
The number of patients documented at each visit, and data
on the termination of treatment are presented in Fig. 1. The
most frequent reasons for early discontinuation were lack
of effectiveness (47 patients, 5.72%) and AEs (26 patients,
3.16%). The mean duration of treatment was 2.26 months,
ranging from 5 days to over 12 months; overall, the dura-
tion of treatment was greater than 138 patient-years.
Patient characteristics
Baseline patient demographics, ADHD diagnosis and the
most frequent concomitant diseases are presented in
Table 1. More boys than girls were included in the study,
and the mean age was 10.04 years, with no difference
between boys and girls; the most common age was 9 years
(16.71%). The majority of children (58.09%) attended
primary school, most frequently third grade (8- to 9-year-
olds). Most patients had a disturbance of activity and
attention (ICD code F90.0), which is similar to ADHD
combined type according to DSM-IV, followed by hyper-
kinetic conduct disorder (F90.1) and other HKD (F90.8).
Hyperkinetic conduct disorder was more frequent in boys,
and other HKDs were less frequent in patients aged 11 and
under (5.94% versus 12.08%), particularly in boys. The
time when ADHD was most impairing (counting multiple
responses) was the school morning (81.10%), followed by
early afternoon (69.34%), late afternoon (51.06%), early
morning (43.55%) and evening (33.29%), according to
physician ratings based on parent information.
A total of 574 (69.83%) children had been treated pre-
viously with other MPH formulations, such as MPH-IR
(most often Medikinet
, Medice, Germany) once or several
times daily or MPH-MR (most often Medikinet
 XL,
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had received a different pharmacological therapy, such as
atomoxetine or amphetamine. A total of 208 (25.30%)
children were treatment naı ¨ve. A total of 262 (31.87%)
children had received non-pharmacological treatments,
most commonly ergotherapy (physical activity and exer-
cise) and behavioural therapy, in addition to pharmaco-
logical therapy or as the only treatment. The main reasons
for switching therapy (counting multiple responses) were
insufﬁcient overall effectiveness of the previous treatment,
including problems with effectiveness such as ﬂuctuations
or effects lasting too long (55.11%), too short an effect
(50.86%), unwillingness to take a second dose at school
(27.63%), problems remembering to take the second or
third dose (20.09%), side-effects (8.95%), too late an onset
of effect (5.02%) or other reasons (12.09%).
ADHD-CGI-S scores for core symptoms at baseline
indicated that 17.17% of patients entering the study had
mild symptoms, 59.14% had moderate symptoms, and
22.44% had severe symptoms. ADHD-associated problems
were rated mild in 32.55% of patients, moderate in 48.08%
and severe in 12.23%. Inattention was the most severe of
the core symptoms, with a mean (SD) score of 2.1 (0.75),
and learning difﬁculties were the most severe associated
symptom, with a mean (SD) score of 1.83 (0.93).
The SDQ-P questionnaire (completed by parents)
showed that 67.13% of patients had an overall difﬁculty
score of abnormal, in contrast with the reference population
852 subjects recruited
Implausible or suspect data (n = 30)
Visit 2 (n = 807)
Only 1 visit completed (n = 9)
Only 2 visits completed (n = 36):
    Visits 1 and 3 (n = 6)
    Visits 1 and 2 (n = 30)
All visits completed (n = 777)
Termination of treatment
at/before visit 2 (n = 15)
Continuation of treatment
intended at visit 2, but no visit 3
(n = 10)
Treatment status not specified at
visit 2 and no visit 3 (n = 1)
Termination of treatment
at/before visit 3 (n = 66)
Treatment status not specified at
visit 3 (n = 43)
Only 1 visit completed (n = 9)
Termination of treatment at end
of study (n = 46)
Lost to follow-up (n = 63)
Visit 3 (n = 783)
Evaluable subjects
Visit 1 (n = 822)
Continuation of treatment at
end of study (n = 632)
Fig. 1 Patient ﬂow through the
study (intent-to-treat
population)
Table 1 Baseline
demographics and disease
characteristics
ADHD attention deﬁcit
hyperactivity disorder, BMI
body mass index, SD standard
deviation;
a N = 816 patients;
b N = 808;
c N = 764;
d N = 786;
e N = 758;
f ADHD diagnosis is not
speciﬁed for 46 patients
Total Male Female
Baseline demographics (N = 822)
Patients, n (%)
a 816 (100) 663 (81.25) 153 (18.75)
Age, years (mean [SD])
b 10.04 (2.47) 10.06 (2.47) 9.94 (2.49)
Height, cm (mean [SD])
c 143.75 (15.10) 144.01 (15.37) 142.54 (13.90)
Weight, kg (mean [SD])
d 37.98 (13.60) 38.18 (13.41) 37.08 (14.46)
BMI, kg/m
2 (mean [SD])
e 17.91 (3.41) 17.92 (3.27) 17.83 (3.97)
ADHD diagnosis, n (%) N = 776
f N = 634 N = 142
F90.0: disturbance of activity/attention 430 (55.41) 345 (54.42) 85 (59.86)
F90.1: hyperkinetic conduct disorder 282 (36.34) 246 (38.80) 36 (25.35)
F90.8: other hyperkinetic disorders 64 (8.25) 43 (6.78) 21 (14.79)
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123expected value of 10% [38]. The difference from the ref-
erence population was apparent in all SDQ subscales:
emotional symptoms (35.73% abnormal, 15.79% border-
line and 48.48% normal), conduct problems (42.30%
abnormal, 15.67% borderline and 42.02% normal),
hyperactivity (57.20% abnormal, 14.54% borderline and
28.25% normal) and peer relationship problems (35.60%
abnormal, 14.13% borderline and 50.28% normal). The
difference was less pronounced only in pro-social behav-
iour (14.27% abnormal, 14.40% borderline and 71.33%
normal).
Administration of Equasym XL

Dosing data are presented in Fig. 2. The daily dose of
Equasym XL
 administered during the study ranged from
10 mg to 120 mg; the maximum recommended daily dose
(60 mg/day) was exceeded in six patients. As expected, the
daily MPH dosage during previous treatment was sub-
stantially lower for patients receiving MPH-IR once daily
compared with those receiving of MPH-IR administered
several times per day or MPH-MR.
On average, at Visit 1, the physician prescribed Equ-
asym XL
 at a higher dosage than prior medication in the
group previously treated with once-daily MPH-IR, at a
similar dosage in the group previously treated with repe-
ated MPH-IR, and at a lower dosage in the group previ-
ously treated with an alternative MPH-MR formulation. In
the subgroup with no previous medication, the mean pre-
scribed dosage of Equasym XL
 was lower than all the
other subgroups. Dosages slightly increased from Visit 1 to
Visit 3, indicating that the physician prescribed Equasym
XL
 according to recommended clinical practice, i.e.
starting with a lower dose and subsequently titrating up
according to the needs of the patient.
Effectiveness
Statistical analyses of effectiveness outcomes are summa-
rised in Table 2. For all outcome measures, a statistically
signiﬁcant decrease was found in ADHD symptoms, ODD
symptoms and associated functional impairment, as well as
an increase in attention-reﬂexivity as rated by parents,
teachers and clinicians. These results remain statistically
signiﬁcant after Bonferroni correction for multiple testing,
and effect sizes vary from a small effect (Cohen’s
d = 0.30) to a large effect (Cohen’s d = 1.17); the largest
change was observed for CGI-S (Cohen’s d = 1.17).
According to CGI-I ratings, ADHD core symptoms
improved during treatment with Equasym XL
 in 524/692
(75.73%) patients, stayed unchanged in 123 (17.77%) and
worsened in 45 (6.50%) (Fig. 3a). Similarly, ADHD-
associated problems improved in 451/676 (66.71%) chil-
dren, remained unchanged in 182 (26.92%) and worsened
in 43 (6.37%) (Fig. 3b).
The severity proﬁle of core symptoms and associated
problems at Visit 1 and at the last visit after Visit 1 (either
Visit 2 or Visit 3), according to CGI-S ratings, is shown in
Fig. 4: Improvement was observed in all symptoms and
problems, with a particularly strong reduction in core
symptoms and learning difﬁculties.
At the ﬁnal examination after 6–12 weeks of treatment
(Visit 3), physicians were asked to provide a global eval-
uation of the effectiveness of Equasym XL
 according to
their medical judgement. This was collected for 721 chil-
dren, and effectiveness was rated as very good in 255
patients (35.37%), good in 312 (43.27%), moderate in 108
(14.98%) and poor in 46 (6.38%).
Large reductions in ADHD symptoms were also found
for parent-rated ADHD symptoms according to ICD-10/
DSM-IV (Table 2, FBB-ADHD, ADHD total: Cohen’s
Equasym XL®
Visit 3
Equasym XL®
Visit 2
Equasym XL®
Visit 1
Previous
treatment
(baseline)
1.0
0.9
0.8
0.7
0.6
0.5
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MPH-IR once daily
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Fig. 2 Previous treatment dose
by body weight at baseline and
Equasym XL
 dose by body
weight prescribed at Visit 1,
Visit 2 and Visit 3, by prior
treatment subgroup. MPH-MR,
modiﬁed-release
methylphenidate; MPH-IR,
immediate-release
methylphenidate; SE standard
error
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123Table 2 Statistical analysis summary of CGI-S, parent and teacher FBB-ADHD and DAYAS scores
Scales N Assessment point Main effect MANOVA and effect size
Visit 1 Visit 2 Visit 3 F* Cohen’s d
(Visit 1–Visit 3)
Mean SD Mean SD Mean SD
Clinical rating
Global impression (CGI-S) 634 2.02 0.67 1.43 0.69 1.07 0.65 447.5 1.17
Parent ratings (FBB-ADHD)
Inattention 701 1.87 0.63 1.35 0.60 1.21 0.58 334.5 0.95
Hyperactivity/impulsivity 699 1.43 0.79 1.02 0.70 0.86 0.65 256.4 0.85
ADHD total 699 1.63 0.62 1.17 0.59 1.02 0.56 356.2 1.00
Functional impairment 698 1.83 0.73 1.38 0.73 1.15 0.71 238.2 0.82
Attention-reﬂexivity 699 0.88 0.62 1.14 0.64 1.22 0.65 87.8 0.49
Teacher ratings (FBB-ADHD)
Inattention 522 1.60 0.73 1.27 0.67 1.11 0.66 123.5 0.69
Hyperactivity/impulsivity 521 1.07 0.85 0.81 0.73 0.68 0.66 73.3 0.53
ADHD total 520 1.31 0.71 1.02 0.63 0.88 0.59 110.9 0.65
Functional impairment 519 1.50 0.89 1.17 0.80 0.98 0.76 98.8 0.62
Attention-reﬂexivity 511 0.98 0.63 1.16 0.64 1.24 0.63 44.5 0.41
Day proﬁle-parent (DAYAS-P)
Total score
Morning before school 682 1.37 0.77 1.08 0.73 1.02 0.72 96.1 0.51
Afternoon 668 1.51 0.68 1.09 0.63 0.94 0.61 209.4 0.78
Late afternoon 685 1.61 0.68 1.30 0.64 1.20 0.64 125.1 0.59
Evening 683 1.48 0.74 1.29 0.72 1.20 0.72 56.4 0.40
ADHD symptoms
Morning before school 681 1.38 0.81 1.09 0.78 1.02 0.78 80.3 0.47
Afternoon 667 1.55 0.71 1.11 0.66 0.94 0.64 217.0 0.77
Late afternoon 682 1.65 0.70 1.35 0.65 1.25 0.67 103.3 0.54
Evening 679 1.50 0.77 1.32 0.76 1.23 0.76 41.7 0.35
ODD symptoms
Morning before school 678 1.28 0.88 1.01 0.79 0.95 0.79 59.8 0.40
Afternoon 660 1.35 0.82 1.01 0.73 0.89 0.71 102.5 0.55
Late afternoon 679 1.49 0.83 1.20 0.77 1.11 0.76 84.3 0.48
Evening 674 1.41 0.87 1.20 0.83 1.13 0.79 45.5 0.36
Day proﬁle-teacher (DAYAS-T)
Total score
Morning ﬁrst half 515 1.07 0.74 0.84 0.64 0.73 0.60 57.3 0.47
Morning second half 494 1.42 0.81 1.10 0.72 0.96 0.69 95.3 0.61
ADHD symptoms
Morning ﬁrst half 515 1.16 0.78 0.91 0.67 0.78 0.63 63.2 0.50
Morning second half 494 1.60 0.85 1.21 0.76 1.06 0.72 111.6 0.66
ODD symptoms
Morning ﬁrst half 514 0.83 0.81 0.67 0.69 0.60 0.66 24.4 0.30
Morning second half 492 1.09 0.91 0.87 0.81 0.74 0.76 42.6 0.41
ADHD attention deﬁcit hyperactivity disorder, CGI-S clinical global impression severity, DAYAS day proﬁle of ADHD assessment, DAYAS-P/T
DAYAS-parent/teacher, FBB-ADHD Fremdbeurteilungsbogen fu ¨r Aufmerksamkeitsdeﬁzit-Hyperaktivita ¨tssto ¨rung, M mean, MANOVA multi-
variate analysis of variance, ODD oppositional deﬁant disorder, SD standard deviation
* All effects are statistically signiﬁcant at P\0.001
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123d = 1.00), while the symptom reduction based on teacher
ratings was in the moderate range (Table 2, FBB-ADHD,
ADHD total: Cohen’s d = 0.65). Figure 5 shows the scores
on the FBB-ADHD scales at Visit 1 and last visit as rated
by parents and teachers. Similar effects were found for the
subscales of hyperactivity/impulsivity and inattention, and
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Fig. 3 CGI-I scores. a Rating
of change of ADHD core
symptoms between Visit 1 and
Visit 3 (n = 692). b Rating of
change of ADHD-associated
problems between Visit 1 and
Visit 3 (n = 676). ADHD,
attention deﬁcit hyperactivity
disorder; CGI-I, clinical global
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123functional impairment was also reduced in both parent
and teacher ratings; conversely, the competency scores
of attention-reﬂexivity increased for both parents and
teachers.
Table 3 shows the percentage of patients below a score
of 1 at Visit 1, Visit 2 and Visit 3 in the ADHD total and
functional impairment FBB-ADHD subscales. The per-
centage of patients in the normal range for ADHD symp-
toms increased from 16.31% in parent ratings and 36.73%
in teacher ratings at Visit 1—54.22 and 64.62% at Visit 3,
respectively. Similarly, the percentage of patients without
functional impairment increased from 10.89% (parents)
and 26.01% (teachers) to 35.96 and 45.86%, respectively.
Teachers and parents also assessed the daily proﬁle of
ADHD symptoms (items 1–3), ODD symptoms (items 4–5)
and problematic behaviour (item 6) using the DAYAS
questionnaire. For all periods of the day, a statistically
signiﬁcant improvement in ADHD symptoms, ODD
symptoms and overall rating was observed (Table 2).
Figure 6 shows the changes in ADHD symptoms from Visit
1 to Visit 3 in the different periods of the day, in terms
of effect sizes as calculated in Table 2. The strongest
symptom changes were observed in the second half of the
school morning (rated by teachers) and in the early after-
noon (rated by parents), while changes in the ﬁrst half of
the school morning (teachers) and in the late afternoon
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Table 3 Percentage of patients
below a score of 1 in the ADHD
total and functional impairment
ratings at Visit 1, Visit 2 and
Visit 3 (FBB-ADHD)
ADHD attention deﬁcit
hyperactivity disorder, FBB-
ADHD Fremdbeurteilungsbogen
fu ¨r Aufmerksamkeitsdeﬁzit-
Hyperaktivita ¨tssto ¨rung
Rating N (total) Visit 1 Visit 2 Visit 3
n % n % n %
Parents
ADHD total 699 114 16.31 302 43.20 379 54.22
Functional impairment 698 76 10.89 185 26.50 251 35.96
Teachers
ADHD total 520 191 36.73 277 53.26 336 64.62
Functional impairment 519 135 26.01 196 37.76 238 45.86
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123(parents) were somewhat lower. The smallest changes were
observed in the early morning and in the evening at home
(both rated by parents).
Safety
Overall, 313 AEs were recorded in 209/822 patients
(25.43%). For 93 AEs (mainly tics) in 88 patients, the
physician failed to specify whether the AE occurred under
previous treatment or current treatment; these events are
included here to provide a conservative analysis. One
patient had six AEs, three patients had ﬁve AEs, four
patients had four AEs, 16 patients had three AEs, 43
patients had two AEs, and 142 patients had only one AE.
The most frequent AEs, by MedDRA 11.1 preferred code,
were psychiatric disorders (19.83% of all patients),
metabolism and nutrition disorders (2.43%) and gastroin-
testinal disorders (2.19%). A list of AEs showing a fre-
quency higher than 0.30% is presented in Table 4. Most
AEs were mild or moderate in intensity, although 47 events
in 29 patients were considered severe. Severity was unre-
corded for 148 AEs (120 patients).
In total, 38 AEs in 21 patients were classiﬁed as serious
(2.55%); no serious AE resulted in death. In 26 (3.16%)
cases, treatment was discontinued as a result of AEs. At the
end of the study, 104 events in 66 patients (8.03%) had
resolved, 31 events in 25 patients (3.04%) were unresolved,
and 25 events in 17 patients (2.07%) had not changed since
onset; the clinical outcome of 14 AEs in 11 patients
(1.34%) was unknown to the physician, and for 139 AEs in
116 patients (14.11%), there was no information about the
outcome. No action was required for 83 AEs in 64 patients
(7.79%), symptomatic therapy was prescribed for 30 AEs
in 20 patients (2.43%), and the Equasym XL
 dose was
reduced as a consequence of 13 AEs in 11 patients
(1.34%); 6 AEs in 4 patients (0.49%) led to a temporary
interruption of treatment, and 40 AEs in 26 patients
(3.16%) led to treatment discontinuation. A total of 27 AEs
in 18 patients (2.19%) were considered related to the study
treatment, 48 AEs in 34 patients (4.14%) were considered
likely to be treatment related, 70 AEs in 47 patients
(5.72%) were considered possibly treatment related, and 25
AEs in 22 patients (2.68%) were considered unlikely to be
related to treatment.
Physicians assessed the global tolerability of Equasym
XL
 at the ﬁnal examination at Visit 3. Tolerability was
considered to be very good in 415/734 patients (56.54%),
good in 270/734 (36.78%) patients, moderate in 33/734
(4.50%) patients and poor in 16/734 (2.18%) patients. No
global assessment was provided for 88 patients.
Discussion
This large observational study used multiple outcomes and
different raters to assess ADHD proﬁle across the day in a
natural setting and, to our knowledge, is the ﬁrst such
study. Results showed that Equasym XL
 was well toler-
ated and effective for the treatment of children and ado-
lescents with ADHD in daily clinical practice conditions.
The efﬁcacy and safety of this MPH-MR formulation
had previously been assessed in three placebo-controlled
clinical trials [19, 23, 42] and in one 3-week post-mar-
keting study [12]. The population analysed in this study is
similar in terms of demographics, ADHD diagnosis and
severity of ADHD symptoms at baseline to those analysed
in previous trials. However, the observational period of this
post-marketing study is longer; the ﬁnal examination was
in fact carried out after 6–12 weeks of treatment, compared
with 1–3 weeks in clinical trials. Also, the nature of this
study is different to a clinical trial as it is an observation of
real-life treatment providing a comprehensive assessment
with ratings from physicians, parents and teachers. Com-
pared with other observational trials of MPH-MR formu-
lations [12, 18, 24, 26, 35], the OBSEER study is the
largest, and one of the most rigorous, to date.
Three-quarters (75.73%) of patients showed improve-
ments in ADHD core symptoms on the CGI-I scale during
treatment with Equasym XL
 compared with the prior
treatment status (either receiving medication or not), and
only 6.50% of patients had worsened scores. The rate of
improvement was similar to that observed in the previous
open-label Equasym XL
 trial (65% of patients had ratings
of very much or much improved) [12], although the criteria
for efﬁcacy were different. This is similar to results from a
Table 4 AEs, by MedDRA 11.1 preferred code (n = 822)
Adverse event
(MedDRA 11.1)
Number of
AEs
Number of
cases
Frequency
(%)
Tic 106 100 12.17
Aggression 32 31 3.77
Depressed mood 13 13 1.58
Initial insomnia 11 11 1.34
Headache 10 9 1.09
Anorexia 9 9 1.09
Gastrointestinal pain 9 9 1.09
Nausea 9 9 1.09
Sleep disorder 9 9 1.09
Decreased appetite 9 8 0.97
Not evaluable 7 6 0.73
Depression 4 4 0.49
Onychophagia 3 3 0.36
Tremor 3 3 0.36
AE adverse event, MedDRA Medical Dictionary of Regulatory
Activities
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1236-month open-label study of the MPH transdermal system
in adolescents, where 75.9% of patients were classed as
‘very much improved’ or ‘much improved’ on the CGI-I
scale [18]. In a 4-week, open-label study of Concerta in
children (aged 6–13 years), CGI-I scores for ADHD
symptoms were rated as improved for approximately 92%
of patients [26].
Results from FBB-ADHD ratings conﬁrm the CGI-I/S
ﬁndings. For the improvement in symptoms according to
total FBB-ADHD scores from Visits 1 to 3, an effect size
(Cohen’s d) of 1.00 was calculated for parent ratings and
0.65 for teacher ratings. As nearly 70% of patients were
already on medication at Visit 1, these effect sizes might be
considered larger than expected. In one meta-analysis of
randomised controlled trials, effect sizes (standardised
mean difference) of between 0.6 and 1.0 were calculated
for the effects of MPH-MR treatment versus placebo [4].
Another meta-analysis of randomised controlled studies of
short-acting MPH reported a standardised change score
from pre- to post-assessment (mean weighted Cohen’s d)o f
1.53 (95% conﬁdence intervals [CI]: 1.23–1.82) for parent
ratings of ADHD symptoms and 1.83 (95% CI: 1.43–2.12)
for teacher ratings [43].
Furthermore, the percentage of patients in the OBSEER
study in the normal range for ADHD total and functional
impairment scores on the FBB-ADHD, as rated by parents
and teachers, increased from Visit 1 to Visit 3, with 54–65
and 36–46% of patients in the normal range for symptoms
and overall impairment, respectively. By comparison, in
the randomised MTA study, the percentage of patients in
the normal range after 14 months of treatment was 56% for
the group receiving MPH-IR (medication management
group), according to combined ratings of ADHD and ODD
symptoms from parents and teachers [41]. Thus, although
cross-study comparisons must be treated with caution,
particularly for studies with such different designs, results
from this observational trial are comparable with those
from randomised studies.
Similarly, ADHD-associated problems improved in two-
thirds (66.71%) of patients and worsened in only 6.37%. In
teacher and parent assessments, behaviour improved
compared with baseline at all six measured time points
across the day, in particular in the second half of the school
morning and in the early afternoon. These peak effective-
ness times coincided with the times of day patients reported
as being most problematic at the beginning of the study and
covered homework time. Moreover, this day proﬁle in a
real-life situation is consistent with the mean plasma con-
centration of Equasym XL
, which shows a peak 6 h after
ingestion [20]; it is also in line with the pharmacodynamic
proﬁle across the day in a laboratory classroom situation
described in the COMACS study [42], in which maximum
effects were observed 1.5–6 h after administration.
AEs were recorded in one-quarter of patients, and the
number and type of AEs were generally similar to prior
Equasym XL
 clinical trials [12, 19, 23]. However, com-
parison with other studies should be made with caution
because the OBSEER study had a longer period of obser-
vation compared with clinical trials. Although the fre-
quency of tics was over 12% in this study, it was similar to
the frequency (13% [teacher scores] and 7% [parent
scores]) reported for the Equasym XL
 arm of a previous
randomised controlled 3-week trial that excluded patients
with a history of tics [23]. While early studies considered
tics to be a contraindication to the use of stimulants for
hyperactive syndromes [27], more recent evidence suggests
that while stimulants may worsen pre-existing tics [30, 34],
there is no support for an increased risk of ﬁrst-onset tics
[22, 36]. As OBSEER was an observational study, patients
with pre-existing tics were not excluded, neither were pre-
existing and emergent tics differentiated, so conclusions
regarding this issue are limited. The number of serious AEs
was notably higher in this study; 38 serious AEs were in
fact observed in 21 patients out of 822 (2.5%), compared
with one serious AE in one patient out of 310 (0.3%)
treated with Equasym XL
 in another observational study
[12], one serious AE in one patient out of 139 (0.7%) [19]
or no serious AEs out of 155 patients [23] in the previous
clinical trials. As noted earlier, this is possibly due to the
longer period of observation and to the fact that for many
AEs, it could not be excluded that they had already
occurred under the previous medication. In addition, there
was no global assessment of tolerability by physicians for
10.7% of patients, and being an observational study, there
was little or no formal training of investigators for the
assessment of seriousness of AEs, which might account for
the difference in the number of serious AEs compared with
previous trials.
There were several other limitations to this study. First,
this was an open-label study without a control group;
therefore, physicians and parents were not blinded to the
study treatment or dose. Teachers were not formally
informed of the change of treatment, and although they
could have been told by parents or children, most were not
aware. The lower effect sizes in teacher ratings may
therefore be a more realistic picture of the real effects of
Equasym XL
, without the expectation effects that may
have inﬂuenced the ratings by parents and the physician,
who were not satisﬁed with the prior medication or the
untreated status. Secondly, due to the design of the study,
the results for the previously treated group can only be
generalised to a population in which a switch to Equasym
XL
 is planned due to suboptimal effects of the prior
medication. Distinct advantages of this study are the long
period of observation and the use of multiple outcome
measures with multiple informants. As it was an
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123observational study, and no strict exclusion criteria were
applied, this analysis describes the real population treated
in clinical practice [39].
In conclusion, this study conﬁrmed the effectiveness of
Equasym XL
 under the conditions of daily practice in
which treatment with Equasym XL
 was planned, as the
response to treatment was positive for the majority of
patients; the improvements observed are particularly
striking because most children had already been treated
with different formulations of the same active substance.
The frequency and nature of AEs observed here are con-
sistent with earlier studies. These results also suggest that
Equasym XL
 covers daily requirements effectively, in
particular in the parts of the day when ADHD symptoms
tend to be most impairing, possibly as a result of its 30:70
IR to MPH-MR content and/or its greater ease of
administration.
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